Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pfizer has partnered with Samsung Medical Center to jointly analyse tumors from Korean patients to generate gene expression profiles that may direct therapies and enhance clinical outcomes in the patients with liver cancer.
Subscribe to our email newsletter
The new research is expected to be conducted in Samsung Medical Center in Seoul. Pfizer said that it expanded into the market for targeted anticancer agents with the launch of Sutent, an anticancer agent used to treat an advanced form of kidney cancer.
Pfizer had signed a memorandum of understanding with the Ministry of Health and Welfare in 2007, agreeing to invest $300m in R&D in Korea. As part of its commitment, the company also formed a strategic partnership with the Korea Research Institute of Bioscience and Biotechnology.
Choi Han-Yong, president of Samsung Medical Center, said: “We are pleased to have an opportunity to work with Pfizer to better understand cancer in Korean patients.”
Neil Gibson, vice president of oncology research unit in Pfizer, said: “This partnership will serve as an opportunity to combine Pfizer’s know-how in drug development and Samsung Medical Center’s genome information and technology in the liver cancer area.
“We further plan to share the ownership of collected and analysed data with Samsung Medical Center, contributing to advance of a variety of oncology research in Korea.”